Galderma Group Valuation
Is PY30 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PY30 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PY30 (€18) is trading below our estimate of fair value (€37.9)
Significantly Below Fair Value: PY30 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PY30?
Key metric: As PY30 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is PY30's PS Ratio? | |
|---|---|
| PS Ratio | 5.5x |
| Sales | US$4.32b |
| Market Cap | US$23.65b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.1x |
| Enterprise Value/EBITDA | 31.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does PY30's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.9x | ||
BAYN Bayer | 0.4x | 1.0% | €19.6b |
MRK Merck KGaA | 3x | 4.1% | €62.2b |
DMP Dermapharm Holding | 1.7x | 4.1% | €2.0b |
PSG PharmaSGP Holding | 2.6x | 7.7% | €287.8m |
PY30 Galderma Group | 5.5x | 11.6% | €21.0b |
Price-To-Sales vs Peers: PY30 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the peer average (1.9x).
Price to Sales Ratio vs Industry
How does PY30's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 23 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 23 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: PY30 is expensive based on its Price-To-Sales Ratio (5.5x) compared to the European Pharmaceuticals industry average (2.9x).
Price to Sales Ratio vs Fair Ratio
What is PY30's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PY30's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R74.3b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R9.00
7D
0.6%
1Y
5.3%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.71
7D
0.4%
1Y
-33.2%
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
E2Z
€8.45
7D
1.1%
1Y
2.9%